• Stempeutics in partnership with , MIRM, Manipal Hospital, and ISCT, is organizing Stem Cell Awareness Day on the 10th April 2015, which brings together organizations and individuals around the world working to ensure that we realize the benefits of one of the most promising fields of science in our time.

  • Stempeucel

    The company's lead product stempeucel®, is ex-vivo cultured adult allogeneic mesenchymal stem cells derived by using a novel pooling technology from multiple bone marrow donors and can be used as an 'off-the-shelf' cryopreserved stem cell product.

  • Stempeutron

    It is an automated, point-of-care medical device for isolation of therapeutic stem and stromal cells from aspirated fat/adipose tissue. Adipose tissue stroma is a rich source of mesenchymal stem cells and endothelial progenitor cells, as well as other tissue-building cells such as vascular smooth muscle cells, pericytes, pre-adipocytes and fibroblasts.

  • Stempeucare

    It is in the pipeline as an over-the-counter product for cosmetic applications. We have identified a set of key bioactive factors derived from adult stem cells and are investigating the potential of such factors for cosmetic applications such as skin rejuvenation and hair growth.


Stempeutics Research is a leading Stem-Cell Company developing stem cell based medicinal products, with facilities in Bangalore and Manipal (India) as well as in Kuala Lumpur (Malaysia). It was incorporated in Jan 2006. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team.

Currently Stempeutics is developing 3 products:


Company's flagship product is "stempeucel®". It is based on allogeneic mesenchymal stem cells derived from bone marrow of healthy, adult voluntary donors. Stempeutics has completed preclinical studies demonstrating the safety and efficacy of "stempeucel®" and currently focusing on indications covering the disease areas of Cardiovascular, Orthopaedics, Endocrinology, and Gastroenterology, where it believes that "stempeucel®" can improve the clinical outcomes substantially. Stempeutics is the FIRST Company to get approval from DCGI (Indian FDA) for conducting stem cell clinical trials in India in 2009 and from NPCB (Malaysian FDA) in 2011.
Currently three Phase 2 clinical trials are in progress in India which are approved by DCGI i.e. Critical Limb Ischemia (CLI), Osteoarthritis (OA) and Liver Cirrhosis (LC). Stempeutics is planning to complete OA & CLI Phase 2 trial by middle of 2013 and likely to file for Phase 3 by end of 2013 based on the outcomes of Phase 2 trial. Stempeutics has also received approval from DCGI to conduct Phase 2 clinical trials for Chronic Obstructive Pulmonary Disorders (COPD) and Diabetes Mellitus Type-II (DM). These two trials are yet to start. In Malaysia, Stempeutics is currently conducting OA Phase 2 trial. Stempeutics has also received NPCB approval for Phase 1/2 Ischemic Cerebral Stroke (CS) trial. This trial is yet to start.
With three Phase 2 trials in progress, Stempeutics aims to bring out their first product into the Indian and Malaysian markets in 2015. Stempeutics long-term objective is to market "stempeucel®" in the Asian, European and North American markets.


Stempeutron is an innovative point-of-care, fully automated stem cell isolation device - to obtain a population of cells, collectively known as the stromal vascular fraction (SVF) from adipose or fat tissue. Autologous SVF cells have significant potential in plastic and reconstructive surgery applications such as soft tissue augmentation for post mastectomy breast reconstruction / cosmetic breast augmentation, facial restructuring, deformity correction, scar and wrinkle reduction etc. Stempeutron will be the FIRST device to be developed indigenously, complying with international regulatory standards, and will be based on an entirely novel process and technology as compared to the few existing devices worldwide for cosmetic and reconstructive therapy. The Alpha phase of the device development is completed and the Beta phase development is in progress. Stempeutics is planning to launch Stempeutron device in 2014 for the Asian market.


stempeucare is a novel product from the Conditioned Medium, for Cosmetic applications. It is a topical application product. Initial proofs of concept studies have shown encouraging results and the product is undergoing further development for Skin Health & Hair Growth. Conditioned Medium derived from BM-MSCs contain a large number of cytokines and growth factors that can facilitate creating a favorable localized microenvironment for enhanced tissue regeneration/repair, cyto-protection,neovascularization etc. by activating resident stem cells in the niche environment via paracrine mechanism. Stempeutics has quantified about 30 growth factors/cytokines in the conditioned medium which plays an important role in tissue regeneration/repair. Based on the patent pending production technology Stempeutics produces consistently homogeneous conditioned medium which can be used to develop cosmetic products having applications in anti-ageing and anti-wrinking of skin; and hair growth promotion. Stempeutics is planning to launch this product in 2014.

Scientists working at Stempeutics have filed over 25 patents and have published over 50 peer reviewed international publications. Stempeutics is committed to deliver safe, effective and affordable stem cell products in a "Bench to Bedside" approach.


Stempeutics - A Venture of Cipla


Manipal Education & Medical Group

Cipla Ltd

Manipal Foundation


BIO Excellence Award

Padma Bhushan

Padma Bhushan

BIONEXUS status to
BIO Excellence Award 2013 Padma Bhusan Dr. Y.K. Hamied
Cipla Ltd.
Padma Bhusan Dr Ramdas Pai
Manipal Education & Medical Group